Aurobindo Pharma has announced that the Hon’ble High Court of Telangana has dismissed a writ petition filed by members of its promoter group. The legal challenge concerned a directive to deposit ₹6.53 crore, representing profits from share trading, into the Investor Protection and Education Fund. The company has confirmed that the court order is directed solely at the individual promoters and entities, and will have no impact on the company’s financial or operational performance.
Background of the Legal Proceedings
The legal matter originated from a settlement application previously filed by members of the company’s promoter and promoter group, including Mr. P. V. Ramprasad Reddy, Ms. P. Suneela Rani, Mr. Kambam Prasad Reddy, and Trident Chemphar Limited. Following a settlement order passed on May 6, 2020, the authorities issued a directive on October 23, 2020, requiring the petitioners to deposit profits amounting to ₹6.53 crore, plus interest accrued at 12% per annum.
High Court Decision
The promoters had sought to set aside the communication regarding the payment through a writ petition filed before the Hon’ble High Court of Telangana. In an order dated May 6, 2026, which was received by the company on May 15, 2026, the Court dismissed the petition. The promoters are currently reviewing the court’s decision in consultation with their legal advisors to determine their next course of action.
Impact Assessment
Aurobindo Pharma has clarified that the court’s ruling pertains exclusively to the individuals and entities named in the petition. Consequently, there is no material impact on the company’s financial health, daily operations, or business activities. The company maintains that its core operations remain unaffected by these developments.
Source: BSE
